



LIBRARIES
UNIVERSITY OF WISCONSIN - MADISON

Cardilate advertisement.

[s.l.]: [s.n.], 1982

<https://digital.library.wisc.edu/1711.dl/CUQCHABPNJQEE8D>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.

Your Angina patients could fly coast to coast on the long-acting effects of one 10mg tablet.

Bioavailability findings* of Oral, Sublingual and Chewable Cardilate® dosage forms in volunteers demonstrated that the Oral (swallowed) 10mg Tablet provided a 6-hour duration of pharmacologic effect; more than 3 times longer than when given sublingually, or as the chewable Tablet. Cardilate Oral Tablets are recommended for the prophylaxis and long-term treatment of patients with frequent or recurrent anginal pain and reduced exercise tolerance associated with angina pectoris.

*Hannemann, R. E., Erb, R. J., Stoltman, W. P., Bronson, E. C., Williams, E. J., Long, R. A., Hull, J. H. and Starbuck, R. R.: Digital Plethysmography For Assessing Erythryl Tetranitrate Bioavailability. Clin Pharmacol and Ther 29:35-39, 1981.

Cardilate® (erythryl tetranitrate) Tablets

INDICATIONS: Cardilate (Erythryl Tetranitrate) is intended for the prophylaxis and long-term treatment of patients with frequent or recurrent anginal pain and reduced exercise tolerance associated with angina pectoris rather than for the treatment of the acute attack of angina pectoris since its onset is somewhat slower than that of nitroglycerin.

CONTRAINDICATIONS: Hypersensitivity or idiosyncratic reaction to organic nitrates.

WARNINGS: The use of nitrates in acute myocardial infarction or congestive heart failure should be undertaken only under close clinical observation and / or in conjunction with hemodynamic monitoring.

PRECAUTIONS: Use with caution in patients with severe liver or renal disease. Tolerance to this drug, and cross-tolerance to other nitrates, may occur. Cardilate should be given to a pregnant woman only if clearly needed. Caution should be exercised when Cardilate is administered to a nursing woman. Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: The most frequent adverse reaction in patients treated with Cardilate is headache. Other adverse reactions occurring are the following: cutaneous vasodilatation with flushing, and transient episodes of dizziness and weakness, plus other signs of cerebral ischemia associated with postural hypotension. Occasional individuals exhibit marked sensitivity to the hypotensive effects of organic nitrates, and severe responses (e.g., nausea, vomiting, weakness, restlessness, pallor, perspiration and collapse) can occur even with the usual therapeutic dose. Alcohol may enhance this effect. Drug rash and / or exfoliative dermatitis may occasionally occur.

DOSAGE AND ADMINISTRATION: Oral / Sublingual Tablets: Cardilate (Erythryl Tetranitrate) may be administered either sublingually or orally. Therapy may be initiated with 10 mg, prior to each anticipated physical or emotional stress and at bedtime for patients subject to nocturnal attacks. The dose may be increased or decreased as needed.

HOW SUPPLIED: TABLETS
(Scored) for ORAL or
SUBLINGUAL USE
5 mg: Bottle of
100, 10 mg:
Bottles of
100 and
1000.

Burroughs Wellcome Co.
Research Triangle Park
North Carolina 27709

